Press Release

Global Premenstrual Syndrome Treatment Market to Surge at a CAGR of Around 3.7% During 2024-30

The Global Premenstrual Syndrome Treatment Market is anticipated to grow at a CAGR of about 3.7% during the forecast period of 2024-30, cites MarkNtel Advisors in the recent research report. The market growth has been attributed to the increasing involvement of women in the labor force. As women get involved in jobs that require sitting for longer durations, and reduce their physical activity, their health depreciates. These situations also cause high levels of stress, anxiety, etc., which has been resulting in hormonal imbalances among women. Hence, with the rise in hormonal imbalance, instances of premenstrual syndromes like cramps, mood swings, etc. happen normally. Thus, to control the effects of these systems on the quality of their work, women tend to opt for PMS treatment solutions, which have been driving the market growth.

Furthermore, female students have also been experiencing increased instances of PMS recently, mainly driven by enhanced academic pressure. As students have several burdens related to assignments, exams, etc., during their university and college time, they tend to develop conditions, that affect their hormonal balance, leading to the frequent prevalence of PMS. Hence, to avoid any effect of PMS symptoms on their academic performance, they have been seeking medications to treat these conditions. Moreover, the awareness among female scholars regarding the impact of PMS on their performance is also improving, owing to which, the demand for PMS medication would grow. This would positively impact the market growth in the coming years, further states the research report, “Global Premenstrual Syndrome Treatment Market Analysis, 2024.”

Segmentation Analysis

Oral Contraceptives Segment Captured Major Market Share

Based on the drug type, the market is further categorized into Antidepressants, Analgesics, Oral Contraceptives, Ovarian Suppression Agents, and others. Among these, oral contraceptives have been the first choice of treatment for premenstrual syndrome among women. This has been largely attributed to the significant advancements in oral contraceptives recently, which included progestogen, which largely helps in catering to PMS symptoms. Further, a range of symptoms including bloating, stomach pain, headache, etc. hinders working women from effectively continuing their job. As oral contraceptives have been observed to act on the reduction of most of these symptoms, they have become the first choice for PMS treatment among women. Consequently, the demand for Oral Contraceptives has increased, propelling the segmental market growth.

North America Leads Premenstrual Syndrome Treatment Industry

North America has been the most prominent region in the market, which has been mainly attributed to the enhanced awareness among women regarding their reproductive health. Moreover, North American governments have been largely focusing on increasing self-dependency among women across the region, owing to which they have been pushing women to join the workforce. Hence, as more women across the region are aware of the syndrome, and its effects on their work performance, they easily identify the pattern, owing to which they tend to adopt medications based on their symptoms.

Nonetheless, women across this region have also been observed to experience significant mental health disorders, which further contributes to the increased instances of PMS. Hence, these factors have been largely driving the demand for PMS medications across the region, and are anticipated to create sufficient demand in the coming years as well. Therefore, all these factors are anticipated to augment the size & volume of the North America Premenstrual Syndrome Treatment Market in the coming years.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market companies, including Bayer AG, Pfizer Inc., Zydus Cadila, Alkem Laboratories Ltd., Kobayashi Pharmaceutical Co., Ltd., Haleon Group of Companies, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Asarina Pharma AB, Lupin, Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd. (Accord Healthcare), Ova Moon, AstraZeneca plc, and others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the regions?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition been shaping up across various regions?
6. How have the buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2019-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?